ANRO (Alto Neuroscience) EBITDA Margin %: 0.00% (As of Mar. 2026)


ANRO Alto Neuroscience Inc ANRO
12 GF Score
Price $25.30
! 1 Warning Sign
View Full Analysis

What is Alto Neuroscience EBITDA Margin %?

Alto Neuroscience ANRO +1.57% 12 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates ANRO with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, Alto Neuroscience ranks worse than 105932.1% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Alto Neuroscience's EBITDA for the three months ended in Mar. 2026 was $-25.51 Mil. Alto Neuroscience's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Alto Neuroscience's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Alto Neuroscience  (NYSE:ANRO) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Alto Neuroscience EBITDA Margin % Related Terms

Alto Neuroscience EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Alto Neuroscience's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alto Neuroscience EBITDA Margin % Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
-4,255.71 0.00 0.00 0.00 0.00

Alto Neuroscience Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ANRO vs MRVI, BBOT, REPL: EBITDA Margin % Comparison

For the Biotechnology subindustry, Alto Neuroscience's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alto Neuroscience EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alto Neuroscience's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Alto Neuroscience's EBITDA Margin % falls into.


ANRO
12GF Score
Alto Neuroscience Inc ANRO
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alto Neuroscience EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Alto Neuroscience's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-60.108/0
= %

Alto Neuroscience's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-25.508/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Alto Neuroscience (ANRO) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alto Neuroscience and its competitors. According to the industry distribution chart, Alto Neuroscience ranks #999999 out of 944 companies in the Biotechnology industry.
Is Alto Neuroscience's EBITDA Margin % too high?
Alto Neuroscience's current EBITDA Margin % is 0.00%. Based on the distribution chart, Alto Neuroscience ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alto Neuroscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alto Neuroscience's EBITDA Margin % compare to MRVI and BBOT?
According to the Biotechnology industry distribution chart, Alto Neuroscience ranks #999999 out of 944 companies for EBITDA Margin %. This places Alto Neuroscience in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alto Neuroscience and its competitors. Alto Neuroscience's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alto Neuroscience stock overvalued right now?
Alto Neuroscience (ANRO) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Alto Neuroscience's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Alto Neuroscience (ANRO), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alto Neuroscience Business Description

Address 650 Castro Street, Suite 450, Mountain View, CA, USA, 94041
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
12GF Score

Get the complete analysis for ANRO

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.30
Price